Related Experiment Video
Updated: Jan 21, 2026
Analysis of DNA Double-strand Break DSB Repair in Mammalian Cells
Published on: September 8, 2010
Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF
Ahmed H Elmenoufy1,2, Francesco Gentile3, David Jay4
1Department of Chemistry , University of Alberta , Edmonton , Alberta T6G 2G2 , Canada.
Abstract:
The ERCC1-XPF heterodimer is a 5'-3' structure-specific endonuclease, which plays an essential role in several DNA repair pathways in mammalian cells. ERCC1-XPF is primarily involved in the repair of chemically induced helix-distorting and bulky DNA lesions, such as cyclobutane pyrimidine dimers (CPDs), and DNA interstrand cross-links. Inhibition of ERCC1-XPF has been shown to potentiate cytotoxicity of platinum-based drugs and cyclophosphamide in cancer cells. In this study, the previously described ERCC1-XPF inhibitor 4-((6-chloro-2-methoxyacridin-9-yl)amino)-2-((4-methylpiperazin-1-yl)methyl)phenol (compound 1) was used as a reference compound. Following the outcome of docking-based virtual screening (VS), we synthesized seven novel derivatives of 1 that were identified in silico as being likely to have high binding affinity for the ERCC1-XPF heterodimerization interface by interacting with the XPF double helix-hairpin-helix (HhH2) domain. Two of the new compounds, 4-((6-chloro-2-methoxyacridin-9-yl)amino)-2-((4-cyclohexylpiperazin-1-yl)methyl)phenol (compound 3) and 4-((6-chloro-2-methoxyacridin-9-yl)amino)-2-((4-(2-(dimethylamino)ethyl) piperazin-1-yl) methyl) phenol (compound 4), were shown to be potent inhibitors of ERCC1-XPF activity in vitro. Compound 4 showed significant inhibition of the removal of CPDs in UV-irradiated cells and the capacity to sensitize colorectal cancer cells to UV radiation and cyclophosphamide.
Insights
New compounds targeting the ERCC1-XPF DNA repair enzyme were synthesized and tested. Compound 4 effectively inhibited DNA repair and sensitized cancer cells to chemotherapy and UV radiation.
Area of Science:
- Molecular Biology
- DNA Repair Mechanisms
- Medicinal Chemistry
Background:
- The ERCC1-XPF endonuclease is crucial for repairing bulky DNA lesions and cross-links.
- Inhibiting ERCC1-XPF can enhance the efficacy of chemotherapy drugs like platinum-based agents and cyclophosphamide.
- Understanding ERCC1-XPF's role is vital for developing novel cancer therapies.
Purpose of the Study:
- To design and synthesize novel ERCC1-XPF inhibitors.
- To evaluate the binding affinity and inhibitory potential of new compounds against ERCC1-XPF.
- To assess the efficacy of lead compounds in cellular DNA repair inhibition and cancer cell sensitization.
Main Methods:
- Docking-based virtual screening (VS) was employed to identify potential ERCC1-XPF inhibitors.
- Seven novel derivatives of a reference inhibitor (compound 1) were synthesized.
- In vitro enzymatic assays, cellular CPD repair assays, and chemosensitization studies were performed.
Main Results:
- Two novel compounds (3 and 4) demonstrated potent inhibition of ERCC1-XPF activity in vitro.
- Compound 4 significantly inhibited cyclobutane pyrimidine dimer (CPD) removal in UV-irradiated cells.
- Compound 4 sensitized colorectal cancer cells to both UV radiation and cyclophosphamide.
Conclusions:
- Novel ERCC1-XPF inhibitors were successfully synthesized and validated.
- Compound 4 shows promise as a therapeutic agent for enhancing cancer treatment efficacy.
- Targeting ERCC1-XPF offers a viable strategy for overcoming resistance to DNA-damaging agents in cancer therapy.
Related Concept Videos
02:25Overview of DNA Repair
Chemically...
02:25Overview of DNA Repair
01:36Mismatch Repair
02:27Base-pairing and DNA Repair
01:54Base Excision Repair
The first step of...
01:08Nucleotide Excision Repair